Table 3

Plasma PK of febuxostat in the presence of verinurad vs febuxostat alone (geometric mean (95% CIs)) (PK population)

Febuxostat
(mg)
Verinurad
(mg)
Patient, nGeometric mean (95% CI)GMR (%) (90% CI)
Cmax (µg/mL)AUC0-24 (µg·h/mL)Cmax AUC0-24
400590.698 (0.625 to 0.780)3.10 (2.83 to 3.40)
2.5120.626 (0.481 to 0.816)2.76 (2.15 to 3.54)91.2 (69.3 to 120)94.2 (88.1 to 101)
5120.517 (0.390 to 0.685)2.50 (2.02 to 3.09)85.6 (75.7 to 96.7)92.4 (89.0 to 95.8)
10240.628 (0.500 to 0.788)3.07 (2.65 to 3.56)88.9 (70.4 to 112)*95.4 (89.4 to 102)*
15230.695 (0.552 to 0.874)2.77 (2.42 to 3.18)116 (89.0 to 152)†88.3 (82.4 to 94.7)†
20110.688 (0.502 to 0.942)2.52 (1.98 to 3.21)114 (92.0 to 141)94.1 (89.4 to 99.0)
800501.47 (1.30 to 1.66)6.85 (6.24 to 7.52)
2.5121.95 (1.46 to 2.62)6.36 (5.01 to 8.09)146 (130 to 165)98.6 (94.5 to 103)
5121.08 (0.77 to 1.53)5.19 (4.27 to 6.31)89.9 (68.8 to 117)89.3 (82.8 to 96.3)
10131.74 (1.58 to 1.91)7.70 (6.64 to 8.94)101 (87.9 to 116)94.2 (90.7 to 97.9)
15112.07 (1.60 to 2.68)6.60 (5.68 to 7.66)123 (88.3 to 173)92.9 (84.1 to 103)
  • AUC0-24, area under the concentration–time curve from time 0 up to 24  hours postdose; Cmax, maximum observed plasma concentration; GMR, geometric mean ratio; t1/2, plasma terminal half-life; Tmax, time of maximum observed plasma concentration.

  • *Cohort 1 (n=12).

  • †Cohort 2 (n=12).